

Progesterone Hypersensitivity Induced by Exogenous Progesterone Exposure

Review began 08/23/2023

Review ended 09/04/2023

Published 09/06/2023

© Copyright 2023

Dhaliwal et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Gurnoor Dhaliwal¹, Jaskaran Batra², Anvitha R. Ankireddypalli³, Swathi Gorle⁴, Ashok Kumar Kanugula⁵, Jasleen Kaur⁶

1. Endocrinology, HealthPartners, Minneapolis, USA 2. Internal Medicine, University of Pittsburgh Medical Center (UPMC), McKeesport, USA 3. Endocrinology, Baptist Health Surgical and Specialty Clinic, Conway, USA 4. Internal Medicine, Wellstar Spalding Regional Medical Center, Griffin, USA 5. Internal Medicine, Wellstar Spalding Regional Hospital, Griffin, USA 6. Endocrinology, Diabetes and Metabolism, HealthPartners, Minneapolis, USA

Corresponding author: Jasleen Kaur, jasleen.x.kaur@healthpartners.com

Abstract

Progesterone hypersensitivity (PH) is a rare hypersensitivity reaction to either endogenous or exogenous progesterone. There are around 200 reported cases of progesterone hypersensitivity in the medical literature. We present the case of a 31-year-old female who presented with cyclical urticaria and angioedema after exogenous progesterone exposure. Her symptoms would begin a few days before her menstrual cycle began and resolve after menstruation. She only had partial recovery of her symptoms with antihistamines, steroids, montelukast, and omalizumab. She needed treatment with oral contraceptives and had a resolution of symptoms, but subsequently developed a recurrence again. Given the rarity of this condition, the diagnosis is often delayed. This diagnosis should be considered for women of reproductive age who present with cyclic hypersensitivity or allergic symptoms.

Categories: Endocrinology/Diabetes/Metabolism, Obstetrics/Gynecology, Allergy/Immunology

Keywords: progesterone, intramuscular progesterone, angioedema, urticaria, autoimmune progesterone dermatitis, progesterone hypersensitivity

Introduction

Progesterone hypersensitivity (PH) is an under-recognized hypersensitivity reaction to endogenous or exogenous progesterone [1]. This condition is almost exclusively seen in women of reproductive age, with symptoms occurring during the luteal phase of the menstrual cycle [2]. The symptoms typically start three to seven days before menstruation, when the progesterone levels peak around day 21 of a 28-day menstrual cycle [3]. The symptoms can last one to three days after menstruation begins. Common symptoms include cutaneous manifestations of urticaria and angioedema. Some women can present with asthma-like symptoms or even anaphylaxis. The diagnosis of this condition is challenging and often delayed due to its rarity and heterogeneous presentation, along with variability in progesterone exposure [4]. Common sources of exogenous progesterone that can result in PH include oral contraceptives, medroxyprogesterone, intrauterine devices containing progesterone, and vaginal rings. The prevalence of this condition is expected to rise in the coming years due to the widespread use of progestins in various contraceptives and fertility treatments [1,5]. Herein, we report the case of a 31-year-old female who developed progesterone hypersensitivity after exposure to exogenous progesterone therapies.

Case Presentation

We report the case of a 31-year-old female presenting with urticaria and angioedema, which occurred three to four days before her menstruation, extending two to three days after her menstruation began (Figures 1-2).

How to cite this article

Dhaliwal G, Batra J, Ankireddypalli A R, et al. (September 06, 2023) Progesterone Hypersensitivity Induced by Exogenous Progesterone Exposure. Cureus 15(9): e44776. DOI 10.7759/cureus.44776



FIGURE 1: Angioedema involving the lips



FIGURE 2: Urticaria involving the lateral aspect of the right thigh

She reported swelling under her eyes and lips and an urticarial rash over her arms, back, buttocks, and thighs. She remained asymptomatic on the remaining days of the menstrual cycle. These episodes started after getting a medroxyprogesterone shot (104 mg) in 2016 for contraception. A day after this shot, she developed angioedema, profuse itching, and urticarial lesions all over her body, which she managed with antihistamines and oral steroids. Despite this history, the patient received another 104 mg medroxyprogesterone shot three months later, which resulted in a recurrence of urticaria and angioedema.

She needed management with diphenhydramine, famotidine, and oral steroids, with some improvement in symptoms. She did not have any past medical problems. She did not have any history of allergies. She had no history of non-steroid anti-inflammatory drug use during menstrual cycles. She had an intrauterine device containing levonorgestrel inserted at the age of 20, which was removed after three to four years.

She became pregnant in January 2019, and her urticaria and hives became challenging to manage. She then had a spontaneous resolution of these skin changes in February and remained relatively symptom-free until her miscarriage in mid-March. She underwent dilation and curettage after the miscarriage, after which her symptoms returned immediately.

She continued to have symptoms around her menstrual cycles. She was then seen in an allergy and immunology clinic. She underwent a workup for hereditary angioedema and chronic spontaneous urticaria (Table 1).

LABS	VALUE	NORMAL RANGE
Hemoglobin	12.3	11.1-15.9 g/dL
WBC	4600	3400-10800/uL
Platelet count	313,000	150000-379000/uL
Neutrophils	62	50-70%
Lymphocytes	28	18-42%
Monocytes	8	4-9%
Eosinophils	2	1-3%
Basophils	0	0-2%
ESR	16	<20 mm/hr
Total immunoglobulin E	4	6-495 IU/mL
Serum C1 esterase inhibitor	29	21-39 mg/dL
C1 esterase inhibitor function	>92	>67% mean normal

TABLE 1: Laboratory evaluation of the patient

WBC: white blood cell count; ESR: erythrocyte sediment rate

She was being managed with double the standard doses of second-generation antihistamines (including cetirizine, levocetirizine, fexofenadine, loratadine, and desloratadine) with partial relief. She even underwent treatment with montelukast (10 mg twice daily) and omalizumab, again with partial relief. Subsequently, due to the cyclic nature of her symptoms and her severe reaction to medroxyprogesterone, there was a concern for progesterone hypersensitivity. She underwent testing for progesterone-specific serum immunoglobulin E (IgE), which came back positive (Figure 3).




FIGURE 3: Results of serum progesterone-specific immunoglobulin E levels, determined using an enzyme-linked immunosorbent assay (ELISA)

OD: optical density; Pos.con: positive control; Neg.con: negative con; CC: patient's initials

This test was performed using an IgE-specific enzyme-linked immunosorbent assay (ELISA). She did not undergo any skin testing.

She was then seen in an obstetrics and gynecology (OB/GYN) clinic and started on cyclic monophasic oral contraceptive therapy to suppress ovulation. She had a complete resolution of symptoms for two to three years, after which the symptoms came back in a cyclical manner. She came to the endocrinology clinic for further management. She was recommended to initiate continuous oral contraceptive pill (OCP) use and skip the placebo pills to provide better control of her symptoms. She expressed her desire to become pregnant in the coming one to two years, so she was also referred to the allergy and immunology clinic for possible desensitization so that she could discontinue OCPs in the future and even avoid worsening symptoms during pregnancy.

Discussion

We have presented the case of a 31-year-old female with progesterone hypersensitivity and a history of exogenous progesterone exposure. She presented with urticaria and angioedema, which only got partially relieved with antihistamines, montelukast, and omalizumab. Her symptoms were resolved by suppressing ovulation with monophasic cyclic oral contraceptive therapy for two to three years. She likely became re-sensitized to progesterone due to the cyclic use of OCPs. She then needed to switch to monophasic continuous OCP use.

Progesterone hypersensitivity is a rare disorder with cutaneous or systemic reactions to exogenous or endogenous progesterone. Most reported cases had prior exposure to an exogenous source [6]. The onset is at any time between menarche and menopause [7]. Presentations can vary from urticarial skin lesions, pruritis, angioedema, and asthma-like symptoms to severe ones like anaphylaxis and Steven Johnson syndrome [6,8-10].

The proposed mechanism behind PH is considered a hypersensitivity reaction, not an autoimmune process [1]. Some patients have presentations of immediate or type 1 hypersensitivity with symptoms related to mast-cell activation like urticaria, angioedema, and anaphylaxis [11]. Some patients have symptoms consistent with delayed or type 4 hypersensitivity [11].

Cyclical aggravation of symptoms is the most significant clue for diagnosis. The diagnosis can also be made using progesterone skin testing (testing type 1 and type 4 hypersensitivity reactions) or a serum-based progesterone-specific IgE immunoassay (testing type 1 hypersensitivity reactions) [12,13]. The sensitivity and specificity of these tests for the diagnosis of PH have yet to be confirmed and can yield equivocal results

[4]. In cases of high clinical suspicion but negative skin or IgE testing, a trial of drugs (OCPs, gonadotrophin receptor (GnRH) agonists, tamoxifen) can be given for three months to confirm the diagnosis [11].

The goals of therapy need to be discussed with the patient and should be determined based on whether the patient desires to be pregnant in the near future. In women who do not want pregnancy, symptoms can be alleviated using antihistamines, topical, or oral glucocorticoids. Long-term control can be achieved with medications that suppress ovulation. These include oral contraceptive therapy, GnRH agonists, and selective estrogen receptor modifiers. Since OCPs contain progesterone, some patients may develop worsening symptoms, and this option cannot be chosen for patients who develop PH secondary to OCP exposure [14]. Patients who fail these strategies need slow or rapid desensitization with oral or intramuscular (IM) progesterone. Patients who are pregnant, undergoing fertility treatments, or who have severe manifestations like anaphylaxis will need rapid desensitization [6]. Omalizumab may be used in refractory cases and cases with anaphylaxis [15]. Bilateral oophorectomy provides definitive management in severe cases refractory to other treatments [16,17].

Conclusions

Women in the childbearing age group presenting with cyclical cutaneous and respiratory systems in the luteal phase and improving a few days after the initiation of menstrual cycles should be evaluated for progesterone hypersensitivity. A timely diagnosis can lead to the institution of therapy based on the patient's desire for pregnancy with care from a multidisciplinary treatment team, including an allergist and immunologist, a reproductive endocrinologist, and/or an OBGYN provider.

Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Buchheit KM, Bernstein JA: Progesterone hypersensitivity: heterogeneous manifestations with a common trigger. *J Allergy Clin Immunol Pract.* 2017, 5:566-74. [10.1016/j.jaip.2017.01.019](https://doi.org/10.1016/j.jaip.2017.01.019)
2. Lee MK, Lee WY, Yong SJ, et al.: A case of autoimmune progesterone dermatitis misdiagnosed as allergic contact dermatitis. *Allergy Asthma Immunol Res.* 2011, 3:141-4. [10.4168/aa.2011.3.2.141](https://doi.org/10.4168/aa.2011.3.2.141)
3. George R, Badawy SZ: Autoimmune progesterone dermatitis: a case report. *Case Rep Obstet Gynecol.* 2012, 2012:757854. [10.1155/2012/757854](https://doi.org/10.1155/2012/757854)
4. Foer D, Buchheit KM: Progesterone hypersensitivity: an evidence-based approach to diagnosis and management in clinical practice. *Immunol Allergy Clin North Am.* 2017, 37:773-84. [10.1016/j.iac.2017.07.006](https://doi.org/10.1016/j.iac.2017.07.006)
5. Patel DH, Fine LM, Bernstein JA: A focused report on progesterone hypersensitivity. *Expert Rev Clin Immunol.* 2023, 19:357-63. [10.1080/1744666X.2023.2182292](https://doi.org/10.1080/1744666X.2023.2182292)
6. Foer D, Buchheit KM, Gargiulo AR, Lynch DM, Castells M, Wickner PG: Progesterone hypersensitivity in 24 cases: diagnosis, management, and proposed renaming and classification. *J Allergy Clin Immunol Pract.* 2016, 4:723-9. [10.1016/j.jaip.2016.03.003](https://doi.org/10.1016/j.jaip.2016.03.003)
7. DeRosa A, Adams S, Fee EK: Progressively worsening cyclic rash: diagnosis and approach to care. *J Am Osteopath Assoc.* 2015, 115:738-44. [10.7556/jaoa.2015.150](https://doi.org/10.7556/jaoa.2015.150)
8. Baptist AP, Baldwin JL: Autoimmune progesterone dermatitis in a patient with endometriosis: case report and review of the literature. *Clin Mol Allergy.* 2004, 2:10. [10.1186/1476-7961-2-10](https://doi.org/10.1186/1476-7961-2-10)
9. Drayer SM, Laufer LR, Farrell ME: Autoimmune progesterone dermatitis presenting as Stevens-Johnson syndrome. *Obstet Gynecol.* 2017, 130:881-4. [10.1097/AOG.0000000000002256](https://doi.org/10.1097/AOG.0000000000002256)
10. Snyder JL, Krishnaswamy G: Autoimmune progesterone dermatitis and its manifestation as anaphylaxis: a case report and literature review. *Ann Allergy Asthma Immunol.* 2003, 90:469-77; quiz 477, 571. [10.1016/S1081-1206\(10\)61838-8](https://doi.org/10.1016/S1081-1206(10)61838-8)
11. Li RC, Buchheit KM, Bernstein JA: Progesterone hypersensitivity. *Curr Allergy Asthma Rep.* 2018, 18:1. [10.1007/s11882-018-0758-x](https://doi.org/10.1007/s11882-018-0758-x)
12. Senila SC, Ungureanu L, Candrea E, Danescu S, Vasilovici A, Cosgarea R, Dionisie V: Progesterone hypersensitivity: case report with favorable evolution. *Exp Ther Med.* 2019, 17:1125-7. [10.3892/etm.2018.7055](https://doi.org/10.3892/etm.2018.7055)
13. Nguyen T, Razzaque Ahmed A: Autoimmune progesterone dermatitis: update and insights. *Autoimmun Rev.* 2016, 15:191-7. [10.1016/j.autrev.2015.11.003](https://doi.org/10.1016/j.autrev.2015.11.003)
14. Toms-Whittle LM, John LH, Griffiths DJ, Buckley DA: Autoimmune progesterone dermatitis: a diagnosis easily missed. *Clin Exp Dermatol.* 2011, 36:378-80. [10.1111/j.1365-2230.2010.05979.x](https://doi.org/10.1111/j.1365-2230.2010.05979.x)
15. Heffler E, Fichera S, Nicolosi G, Crimi N: Anaphylaxis due to progesterone hypersensitivity successfully treated with omalizumab. *J Allergy Clin Immunol Pract.* 2017, 5:852-4. [10.1016/j.jaip.2017.01.003](https://doi.org/10.1016/j.jaip.2017.01.003)
16. Ródenas JM, Herranz MT, Tercedor J: Autoimmune progesterone dermatitis: treatment with oophorectomy.

- Br J Dermatol. 1998, 139:508-11. [10.1046/j.1365-2133.1998.02420.x](https://doi.org/10.1046/j.1365-2133.1998.02420.x)
17. Shelley WB, Preucel RW, Spont SS: Autoimmune progesterone dermatitis. Cure by oophorectomy . JAMA. 1964, 190:35-8.